Our Focus
Our first two preclinical programs in our internal pipeline, ABCL575 and ABCL635, are currently in IND-enabling studies. IND submissions for both ABCL575 and ABCL635 are anticipated in 2025.
In addition, we anticipate additional development candidates will enter IND-enabling studies in 2024 and 2025.
We have developed technology platforms to unlock high-value drug classes, targets, and modalities, including transmembrane proteins, T–cell engagers, and peptide-MHCs.
We are using our platform to develop first-in-class antibody medicines for well-validated complex transmembrane protein targets that have been intractable using traditional approaches.
Learn More
Our T-cell engager platform leverages hundreds of diverse CD3-binding antibodies to create bispecific antibodies that achieve potent tumor-cell killing with reduced cytokine release, which can help address dose-limiting toxicities.
Learn More
Our technology enables discovery of antibodies that are highly specific to MHC-peptide complexes, expanding the accessible target space for T-cell engagers in solid tumors.
Learn MoreOur engine integrates expert teams, technology, and facilities with data science and automation to support the optimized workflows that are necessary to move therapeutic programs from concept through to the clinic.
Today, our engine allows us to advance drug programs through to the delivery of development candidates for IND-enabling studies. We are currently integrating process development, manufacturing, and regulatory capabilities, and when complete, we will be able to advance programs from targets to early clinical development.
We use genetic, cell, and/or protein approaches to immunize multiple species, including rats, wild-type and humanized mice platforms (ATX-Gx™, Trianni® platform and Trianni Mouse® ), camelids, and more.
High-throughput single-cell screening powered by machine vision and high-throughput sequencing.
Lead panel identification by high-throughput functional and biophysical characterization.
Development candidate selection supported by mid-scale expression and detailed characterization.
Clinical candidate selection with large-scale expression, IND-enabling studies, and CMC development.
Clinical manufacturing facility near headquarters for production of GMP drug substance (up to 2,000 L bioreactors) and drug product.